Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yosuke Minami

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
International Journal of Hematology|June 18, 2024
Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL StudyYosuke Minami, Noriko Doki, Hiroshi Matsuoka, et al.
Cancer Medicine|September 28, 2022
Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL studyJunichiro Yuda, Noriko Doki, Hiroshi Matsuoka, et al.
Cancer Science|April 29, 2026
Population-Based Identification of Clonal Hematopoiesis Using Peripheral Blood Whole-Genome Sequencing in JapanSungGi Chi, Ikuko N Motoike, Takao Fujisawa, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2008
BCR-ABL-transformed GMP as myeloid leukemic stem cellsYosuke Minami, Scott A Stuart, Tomokatsu Ikawa, et al.
International Journal of Hematology|December 21, 2019
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R<sup>2</sup>) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphomaKoji Izutsu, Yosuke Minami, Noriko Fukuhara, et al.
International Journal of Molecular Sciences|May 14, 2022
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid LeukemiaSeiichiro Katagiri, SungGi Chi, Yosuke Minami, et al.
Cancer Science|April 22, 2020
Tyrosine kinase inhibitors induce alternative spliced BCR-ABL<sup>Ins35bp</sup> variant via inhibition of RNA polymerase II on genomic BCR-ABLJunichiro Yuda, Jun Odawara, Mariko Minami, et al.
International Journal of Hematology|December 16, 2024
A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02Hironori Arai, Naoko Hosono, SungGi Chi, et al.
Cancer Science|May 31, 2017
Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignanciesYosuke Minami, Hironobu Minami, Toshihiro Miyamoto, et al.
Blood|June 23, 2009
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocationYukimasa Shiotsu, Hitoshi Kiyoi, Yuichi Ishikawa, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
International Journal of Hematology|June 18, 2024
Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL StudyYosuke Minami, Noriko Doki, Hiroshi Matsuoka, et al.
Cancer Medicine|September 28, 2022
Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL studyJunichiro Yuda, Noriko Doki, Hiroshi Matsuoka, et al.
Cancer Science|April 29, 2026
Population-Based Identification of Clonal Hematopoiesis Using Peripheral Blood Whole-Genome Sequencing in JapanSungGi Chi, Ikuko N Motoike, Takao Fujisawa, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2008
BCR-ABL-transformed GMP as myeloid leukemic stem cellsYosuke Minami, Scott A Stuart, Tomokatsu Ikawa, et al.
International Journal of Hematology|December 21, 2019
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R<sup>2</sup>) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphomaKoji Izutsu, Yosuke Minami, Noriko Fukuhara, et al.
International Journal of Molecular Sciences|May 14, 2022
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid LeukemiaSeiichiro Katagiri, SungGi Chi, Yosuke Minami, et al.
Cancer Science|April 22, 2020
Tyrosine kinase inhibitors induce alternative spliced BCR-ABL<sup>Ins35bp</sup> variant via inhibition of RNA polymerase II on genomic BCR-ABLJunichiro Yuda, Jun Odawara, Mariko Minami, et al.
International Journal of Hematology|December 16, 2024
A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02Hironori Arai, Naoko Hosono, SungGi Chi, et al.
Cancer Science|May 31, 2017
Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignanciesYosuke Minami, Hironobu Minami, Toshihiro Miyamoto, et al.
Blood|June 23, 2009
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocationYukimasa Shiotsu, Hitoshi Kiyoi, Yuichi Ishikawa, et al.
Pageof 11